S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:UTHR

United Therapeutics - UTHR Stock Forecast, Price & News

$217.10
-3.31 (-1.50%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$215.41
$224.06
50-Day Range
$216.46
$244.17
52-Week Range
$158.38
$245.48
Volume
556,550 shs
Average Volume
412,339 shs
Market Capitalization
$9.88 billion
P/E Ratio
16.43
Dividend Yield
N/A
Price Target
$250.14

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
15.2% Upside
$250.14 Price Target
Short Interest
Healthy
2.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.38
Upright™ Environmental Score
News Sentiment
0.67mentions of United Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$11.74 M Sold Last Quarter
Proj. Earnings Growth
15.98%
From $15.21 to $17.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.82 out of 5 stars

Medical Sector

50th out of 1,135 stocks

Pharmaceutical Preparations Industry

13th out of 557 stocks

UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $217.10 on Friday. The company has a market capitalization of $9.88 billion, a price-to-earnings ratio of 16.43, a PEG ratio of 4.53 and a beta of 0.53. United Therapeutics has a twelve month low of $158.38 and a twelve month high of $245.48. The stock has a fifty day simple moving average of $229.49 and a 200 day simple moving average of $203.78. The company has a quick ratio of 7.83, a current ratio of 8.10 and a debt-to-equity ratio of 0.19.

United Therapeutics (NASDAQ:UTHR - Get Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing analysts' consensus estimates of $4.10 by ($1.69). United Therapeutics had a return on equity of 15.50% and a net margin of 35.27%. The business had revenue of $466.90 million for the quarter, compared to analyst estimates of $461.06 million. During the same quarter in the previous year, the business posted $3.65 earnings per share. The business's revenue was up 4.6% on a year-over-year basis. Sell-side analysts expect that United Therapeutics will post 15.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on UTHR shares. Oppenheimer upped their target price on United Therapeutics from $275.00 to $300.00 in a research note on Thursday, May 5th. Jefferies Financial Group upped their target price on United Therapeutics from $223.00 to $245.00 in a research note on Tuesday, May 24th. Wedbush upped their target price on United Therapeutics from $236.00 to $263.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 24th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, August 4th. Finally, Credit Suisse Group increased their price target on United Therapeutics from $219.00 to $247.00 and gave the company an "outperform" rating in a research note on Tuesday, May 24th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $250.14.

Insiders Place Their Bets

In other United Therapeutics news, Director Christopher Causey sold 5,000 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $223.54, for a total transaction of $1,117,700.00. Following the completion of the sale, the director now directly owns 750 shares in the company, valued at approximately $167,655. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, Director Christopher Causey sold 5,000 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $223.54, for a total transaction of $1,117,700.00. Following the completion of the sale, the director now directly owns 750 shares in the company, valued at approximately $167,655. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction dated Thursday, May 19th. The stock was sold at an average price of $183.43, for a total value of $1,100,580.00. Following the sale, the executive vice president now owns 36,397 shares of the company's stock, valued at $6,676,301.71. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,712 shares of company stock worth $11,740,574. Company insiders own 12.40% of the company's stock.

Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock News Headlines

United Therapeutics (NASDAQ:UTHR) Downgraded by StockNews.com
United Therapeutics (UTHR) Q2 Earnings Lag Estimates
United Therapeutics Attracts Big Money
Liquidia Vs. MannKind: Treprostinil Is The Big 'IF'
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Company Calendar

Last Earnings
8/03/2022
Today
8/14/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
965
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$250.14
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$203.00
Forecasted Upside/Downside
+15.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$475.80 million
Pretax Margin
44.96%

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Cash Flow
$11.67 per share
Book Value
$94.88 per share

Miscellaneous

Free Float
39,872,000
Market Cap
$9.88 billion
Optionable
Optionable
Beta
0.53

Social Links















UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2022?

6 Wall Street research analysts have issued 1-year target prices for United Therapeutics' stock. Their UTHR share price forecasts range from $203.00 to $300.00. On average, they predict the company's stock price to reach $250.14 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2022?

United Therapeutics' stock was trading at $216.08 on January 1st, 2022. Since then, UTHR shares have increased by 0.5% and is now trading at $217.10.
View the best growth stocks for 2022 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday, August, 3rd. The biotechnology company reported $2.41 EPS for the quarter, missing analysts' consensus estimates of $4.10 by $1.69. The biotechnology company had revenue of $466.90 million for the quarter, compared to analysts' expectations of $461.06 million. United Therapeutics had a trailing twelve-month return on equity of 15.50% and a net margin of 35.27%. The firm's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.65 earnings per share.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (6.14%), FMR LLC (5.91%), Assenagon Asset Management S.A. (1.42%), Pictet Asset Management SA (1.26%), Polaris Capital Management LLC (0.77%) and Northern Trust Corp (0.74%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $217.10.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $9.88 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $13.21 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 965 workers across the globe.

When was United Therapeutics founded?

United Therapeutics was founded in 1996.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.